This study is testing a new treatment called CRB-701 for adults with certain advanced solid tumors that have a protein called nectin-4. CRB-701 is an antibody-drug conjugate (ADC), which means it's designed to deliver a drug directly to cancer cells. Researchers want to find a safe and effective dose of CRB-701, sometimes in combination with another drug called anti-PD-1 (a checkpoint inhibitor). The study will look at how safe CRB-701 is and how well it shrinks tumors. You might be able to join if your cancer expresses nectin-4 and has progressed after other treatments, or if there are no other standard treatments available. For some head and neck cancers (HNSCC), you might be able to join as a first-line therapy. The study plans to enroll 348 participants.

Study design

This is an open-label, Phase 1/2 study with three parts, designed to find the best dose of CRB-701 alone and in combination with anti-PD-1.

What's involved

You will receive CRB-701 through an intravenous infusion. You will also have blood tests, CT or MRI scans, and other assessments to monitor the treatment's effects.

Compensation

Not stated in the trial record.

Follow-up

The study will evaluate how well the treatment works in terms of Objective Response Rate (ORR) for up to 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.